Compare BIO-TECHNE Corp (TECH) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Workiva Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Workiva Inc trades at $75.4 (market cap $4.01B). The key difference: BIO-TECHNE Corp is far larger — about 2.8× Workiva Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Workiva Inc for 21 Days on average.
| TECH | WK | |
|---|---|---|
Market Cap | $11.36B | $4.01B |
Volume | 5,390,331 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $72.61 | $93.31 |
52-Week Low | $43.31 | $44.31 |
Typical Hold Time | 63 Days | 21 Days |
Enterprise Value | $11.39B | $3.99B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
WK trades at $71.53, up 1.95% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and analyst consensus of $86 price target. Revenue grew to $966M in 2026 with net income turning positive at $47M. Recent news highlights AI innovation and inclusion in major indices, supporting positive sentiment.
The outlook remains positive with 89% analyst buy ratings and improving profitability. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in the regulatory software space. The stock offers growth potential but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
